Advisers to the Food and Drug Administration have recommended approval of a new obesity drug called Qnexa. The advisory panel had rejected the drug two years ago due to concerns about possible birth defects and heart problems. But new studies presented by the drug's maker convinced the panel that the benefits of the drug outweighed its risks. The panel did recommend, however, the company that makes the drug conduct a follow-up study to better assess the drug's risk to the heart. The FDA usually follows the advice of its advisers.
When you give to WAMU, your tax-deductible membership gift helps make possible award-winning programs such as Morning Edition, All Things Considered, The Diane Rehm Show, The Kojo Nnamdi Show, and other favorites.